London: Pharma major Pfizer on Wednesday reported that its COVID-19 vaccine is 95 per cent effective in phase 3 trials and would be applying for emergency US authorization within days.
The vaccine, developed with German partner BioNTech SE, has shown no major side effects. It demonstrated 95 per cent efficacy beginning 28 days after the first dose, Pfizer said.
“Additionally, the safety milestone required by the US FDA (Food and Drug Administration) for Emergency Use Authorization (EUA) has been achieved. To date, no serious safety concerns related to the vaccine candidate have been reported,” it said.
“Within days, we plan to submit a request to the US FDA for an EUA based on the totality of safety and efficacy data collected, as well as manufacturing data relating to the quality and consistency of the vaccine candidate,” it added.
The vaccine, however, will be required to be stored and transported at a temperature of minus 70 degrees, which is a huge challenge for countries like India.
NITI Aayog member (Health) and head of National Tast Force on COVID-19 Dr VK Paul has said that sufficient doses of the Pfizer vaccine, as required for the Indian population, will not be available.
Bhubaneswar: Amid preparations for Durga Puja in full swing across Odisha, heavy rains lashed Bhubaneswar…
Bhubaneswar: With the rehabilitation of street vendors evicted from Bada Danda (Grand Road) in Odisha's…
Chennai: The controversy over alleged use of animal fat in making Tirupati laddoos is yet to…
Bhopal: Four days after the biggest drugs bust in Delhi comes another massive seizure. In…
Rourkela: Two persons were arrested and a huge quantity of firecrackers valued at over Rs…
Bhubaneswar: The Odisha Public Service Commission (OPSC) has cancelled the written examination of Optional Subjects…
Bhubaneswar: Intense spells of rain together with lightning may lash Bhubaneswar and Cuttack cities of…
Balangir: Dedicated to the cause of flora and fauna, villagers of Kantapali in Kutasingha panchayat…